VANI Vivani Medical, Inc.

Nasdaq vivani.com


$ 1.52 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:13:25 EDT
QQQ $ 592.59 $ 0.00 (0 %)
DIA $ 456.40 $ 0.00 (0 %)
SPY $ 654.16 $ 0.00 (0 %)
TLT $ 91.52 $ 0.00 (0 %)
GLD $ 399.31 $ 0.00 (0 %)
$ 1.48
$ 1.43
$ 1.42 x 250
$ 1.50 x 1,004
-- - --
$ 0.91 - $ 1.80
530,309
na
87.68M
$ 2.64
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 06-26-2020 03-31-2020 10-Q
23 03-19-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-19-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-15-2018 03-31-2018 10-Q
31 03-20-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-11-2016 12-31-2015 10-K
40 11-16-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vivani-sets-october-8-record-date-for-spin-off-of-cortigent-to-trade-under-nasdaq-ticker-crgt

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only compan...

 vivani-medical-plans-to-initiate-phase-1-clinical-study-in-npm-139-semaglutide-implant-program-in-first-half-of-2026-pending-regulatory-clearance

NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q2-eps-012-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0....

 vivani-medical-announces-the-appointment-of-anthony-baldor-as-chief-financial-officer

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company deve...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q1-eps-011-misses-010-estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0....

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-expands-collaboration-with-okava-pharmaceuticals-to-include-dogs-in-development-of-okv-119-a-long-acting-glp-1-therapy-for-weight-management-diabetes-and-other-cardiometabolic-conditions

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or t...

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 vivani-medical-q4-2024-gaap-eps-011-inline-as-of-december-31-2024-vivani-had-cash-cash-equivalents-and-restricted-cash-totaling-197m-additional-825m-equity-financing-which-secures-solid-financial-position-into-q2-of-2026

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a...

 vivani-medical-plans-private-placement-of-737m-shares-at-112-per-share-expected-to-result-in-gross-proceeds-of-825m

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026. 

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

 hc-wainwright--co-reiterates-buy-on-vivani-medical-maintains-4-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION